A phase II study of dacarbazine, cisplatin, interferon-alpha and high-dose interleukin-2 in 'poor-risk' metastatic melanoma
A phase II study of dacarbazine, cisplatin, interferon-alpha and high-dose interleukin-2 in 'poor-risk' metastatic melanoma
复制标题
DOI：
10.1016/0959-8049(96)00135-9
复制
发表时间：
1996-08-01
影响因子：
8.4
通讯作者：
Keilholz, U
中科院分区：
文献类型：
--
作者：
Proebstle, TM;Scheibenbogen, C;Keilholz, U
患有非常晚期疾病的黑色素瘤患者通常不包括在化学免疫治疗试验中。我们报告了22例黑色素瘤患者，包括5例体能状态降低（Karnofsky PS < 70），8例转移性眼黑色素瘤，6例脑转移瘤，4例接受白细胞介素-2预治疗。用达卡巴嗪（250 mg/m2，第1-3天）、顺铂（30 mg/m2，第1 - 3天）、干扰素-α 2a（IFN-α，10 Mio IU/m2，皮下注射，第1-5天）和IL-2（i. v.，18 Mio IU/m2，持续6、12、24 h，随后在72 h内13.5 Mio IU/m2）。在脑转移的情况下，增加了放射治疗。未发生IV级毒性，无需降低剂量。21例患者可评价缓解。6例（29%）出现疾病进展，5例（24%）部分缓解，10例（48%）疾病稳定。缓解部位包括皮肤、淋巴结、肌肉、肺、胸膜、肝脏、胰腺、肾上腺和脑。所述治疗方案即使在转移性黑色素瘤和预后不良的患者中也是安全和有效的。版权所有（C）1996 Elsevier Science Ltd
Melanoma patients with very advanced disease have usually not been included in chemo-immunotherapy trials. We report on 22 melanoma patients, including 5 with reduced performance status (Karnofsky PS < 70), 8 with metastatic ocular melanoma, 6 with brain metastases, and 4 who had pretreatment with interleukin-2. These were treated with a combination regimen of dacarbazine (250 mg/m(2), days 1-3), cisplatin (30 mg/m(2), days 1-3), interferon-alpha 2a (IFN-alpha, 10 Mio IU/m(2) s.c., days 1-5) and IL-2 (i.v., 18 Mio IU/m(2) for 6, 12, 24 h, followed by 13.5 Mio IU/m(2) in 72 h). In the case of brain metastases radiotherapy was added. No grade IV toxicity occurred and no dose reductions were necessary. 21 patients were evaluable for response. 6 (29%) had disease progression, 5 (24%) had partial response and 10 (48%) had stable disease. Sites of response included skin, lymph nodes, muscle, lung, pleura, liver, pancreas, adrenal gland and brain, The described treatment schedule is safe and active even in patients with metastatic melanoma and poor prognosis. Copyright (C) 1996 Elsevier Science Ltd